A ROS-responsive antibacterial drug nanocarrier and preparation method thereof

By developing ROS-responsive antibacterial drug nanocarriers, using biblock polymers to encapsulate antibacterial agents, the problems of antibiotic resistance and high drug delivery frequency when treating bacterial infections are solved, and efficient antibacterial and anti-inflammatory effects are achieved, promoting Healing of bacterial keratitis and reducing drug precipitation problems.

CN115671298BActive Publication Date: 2024-12-03WENZHOU MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202211456387.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-21
Publication Date
2024-12-03
Estimated Expiration
2042-11-21

AI Technical Summary

Technical Problem

When existing antibiotics treat bacterial infections, the growth and overuse of drug-resistant bacteria lead to poor efficacy, especially in bacterial keratitis, fluoroquinolones have low solubility and high frequency of administration, resulting in limited therapeutic effects.

Method used

Develop a ROS-responsive antibacterial drug nanocarrier, using the biblock polymer P (PEGMA10-co-PBA2)-b-PMTEMA25, which encapsulates antibacterial agents such as fluoroquinolones, forms antibacterial drug-loaded vesicles, and has antioxidant and anti-inflammatory effects, improving drug adhesion and bioavailability.

Benefits of technology

This nanocarrier releases antibacterial agents in a high ROS environment, reduces the dosage of antibacterial drugs, improves bioavailability, enhances antibacterial effects, promotes the healing of bacterial keratitis, reduces the expression of inflammatory factors, and improves the precipitation of eye drugs in the eye.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115671298B_ABST
    Figure CN115671298B_ABST
Patent Text Reader

Abstract

The invention discloses a ROS-responsive antibacterial drug nanocarrier and a preparation method thereof, comprising a diblock polymer P(PEGMA 10 ‑co‑PBA2)‑b‑PMTEMA 25 , and also provide antibacterial drug-loaded vesicles based on the above-mentioned nanocarriers to provide a drug carrier that has both ROS response and antioxidant and anti-inflammatory capabilities. When used as an antibacterial drug carrier, it can synergize antibacterial and anti-inflammatory effects, reduce the dosage of antibacterial drugs, and have good adhesion to bacteria, thereby improving the bioavailability of the drug and achieving better antibacterial treatment effects while reducing the number of drug administrations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antimicrobial drug materials, and in particular to a ROS-responsive antimicrobial drug nanocarrier and a preparation method thereof. Background Art

[0002] Bacterial infection is an acute systemic infection caused by pathogenic bacteria or conditional pathogens invading the blood circulation, growing and multiplying, and producing toxins and other metabolites. Antibiotics are currently the conventional method for treating bacterial infections. Although antibiotics have achieved some success in combating bacterial diseases, the continued increase in the number of antibiotic-resistant bacteria, especially multidrug-resistant bacteria, has weakened the efficacy of antibiotics and led to a high mortality rate from infectious diseases.

[0003] The destructive mechanism of oxygen free radicals in the inflammatory immune microenvironment has attracted more and more attention. During acute inflammatory responses, activated phagocytes, such as granulocytes and macrophages, produce a certain amount of oxygen free radicals to kill pathogens or digest foreign particles, playing a protective role. However, when inflammation is uncontrollable, persistent oxidative stress will lead to the continuous release of oxygen free radicals, causing irreversible tissue and organ damage and the migration of inflammation. Excessive levels of reactive oxygen species can cause a strong inflammatory response in the wound, further worsening the wound. When antibiotics are used alone to treat bacterial infection inflammation, excess reactive oxygen species in local areas may hinder the healing process of bacterial inflammation, and the treatment effect is limited. Increasing the dosage of antibiotics also brings about the problem of antibiotic resistance. Therefore, starting from trying to remove oxygen free radicals and relieve oxidative stress damage, we are looking for an ideal antibacterial, anti-inflammatory, and antioxidant agent for treatment.

[0004] Block copolymer vesicles are hollow structures formed by the oriented assembly of amphiphilic block copolymers in a solvent. They have good structural stability and rich functionality, and are widely used in drug release, nanoreactors, hydrogels and other fields.

[0005] In the prior art, for example, Patent No. CN114796502A discloses a responsive hydrogel drug delivery system, which is composed of a hydrogel matrix, an antibacterial agent, and an anti-inflammatory agent, and can respond to a high ROS environment, and can be programmed to lyse and release the antibacterial agent and anti-inflammatory agent system contained therein, thereby achieving antibacterial and anti-inflammatory effects. However, the anti-inflammatory effect is achieved by adding an anti-inflammatory agent to the drug delivery system.

[0006] Therefore, the purpose of the present invention is to find a new drug carrier that is ROS-responsive and has antioxidant and anti-inflammatory effects.

[0007] Another technical problem to be solved by the present invention is that, in specific applications, bacterial keratitis (BK) is a suppurative keratitis caused by bacterial infection, also known as bacterial corneal ulcer. The condition is often serious. If it is not effectively treated, corneal ulcer perforation or even intraocular infection may occur, and the eyeball may eventually atrophy. The local reaction of corneal bacterial infection usually involves an inflammatory process, which is characterized by the infiltration of inflammatory cells (such as macrophages), the production of reactive oxygen species (ROS), the accumulation of proinflammatory cytokines TNF-α and IL-1β, and proinflammatory lipid mediators. Monotherapy with fluoroquinolones is the first choice for the treatment of BK. However, due to the special structure of the eye, the utilization of eye drops is not high, and the number of drug administrations and the dosage of the drug need to be increased. For antibiotics, excessive use will increase bacterial resistance, which is not conducive to the treatment of the disease. And the solubility of fluoroquinolones at the pH value of tears is low, and precipitation will occur when commercially available ophthalmic solutions are applied, resulting in low ocular bioavailability and ocular irritation. Therefore, the present invention constructs a drug carrier having both anti-inflammatory and adhesive properties to deliver antibiotics to treat bacterial keratitis. Summary of the invention

[0008] In view of the shortcomings of the prior art, the object of the present invention is to provide a new drug carrier with ROS response and antioxidant and anti-inflammatory effects.

[0009] To achieve the above object, the present invention provides a ROS-responsive antibacterial drug nanocarrier, comprising a diblock polymer P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 , the P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 It has the structure shown below:

[0010]

[0011] The present invention also provides an antimicrobial drug-loaded vesicle based on the above-mentioned ROS-responsive antimicrobial drug nanocarrier, which also includes an antimicrobial agent, and the antimicrobial agent is loaded and encapsulated in the drug-loaded vesicle.

[0012] In a specific embodiment of the present invention, the antibacterial agent is a fluoroquinolone.

[0013] In a specific embodiment of the present invention, the antibacterial agent is ciprofloxacin.

[0014] The present invention further provides the use of the antibacterial drug-loaded vesicles in preparing drugs for treating bacterial eye inflammation.

[0015] In a specific embodiment of the present invention, the use is the use of antibacterial drug-loaded vesicles in the preparation of drugs for treating bacterial keratitis.

[0016] The present invention also provides a method for preparing the ROS-responsive antibacterial drug nanocarrier, comprising the steps of: preparing a macromolecular chain transfer agent P(PEGMA 10 -co-PBA 2 )-CTA

[0017] 4-cyano-4-(phenylthioformylthio) valeric acid, polyethylene glycol methacrylate, 3-acrylamidophenylboronic acid and azobisisobutyronitrile were mixed and dissolved in N,N-dimethylformamide, and then the solution was bubbled with nitrogen for 20-60 minutes in an ice bath, and polymerized under nitrogen for 5-10 hours at a low speed under a hot bath condition of 70°C. The resulting solution was exposed to air to terminate the polymerization, and dialyzed in water using a 2000Da dialysis bag, and vacuum freeze-dried to obtain the product macromolecular chain transfer agent P(PEGMA 10 -co-PBA 2 )-CTA;

[0018] Step 2: Preparation of block polymer P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 P(PEGMA) prepared in step 1 10 -co-PBA 2 )-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile were mixed and dissolved in methanol, and then the solution was bubbled with nitrogen in an ice bath for 20-60 minutes, and then stirred at a low speed in a hot bath at 60°C. After polymerization for 10-15 hours under nitrogen, the resulting solution was exposed to air to terminate the polymerization, and the product was centrifuged and washed with methanol. The obtained product was vacuum concentrated and dried to obtain a diblock polymer P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 .

[0019] In a specific embodiment of the present invention, the molar ratio of 4-cyano-4-(phenylthiocarboxymethylthio)pentanoic acid, polyethylene glycol methacrylate, 3-acrylamidophenylboronic acid and azobisisobutyronitrile in step 1 is 1:10:2:0.5.

[0020] In a specific embodiment of the present invention, P(PEGMA 10 -co-PBA 2 The molar ratio of )-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile is 1:25:0.5.

[0021] The present invention also provides a method for preparing antibacterial drug-loaded vesicles, wherein P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 The diblock copolymer was dissolved in N,N-dimethylformamide, and then the CIP aqueous solution was slowly added dropwise under continuous stirring to prepare CIP vesicles. The CIP vesicle dispersion was then transferred to a 7000Da dialysis bag and dialyzed in deionized water for 3 h to remove residual N,N-dimethylformamide and free CIP to obtain drug-loaded vesicles CIP@PPM.

[0022] The present invention has the following advantages:

[0023] The present invention provides a drug carrier that has both ROS response and anti-oxidation and anti-inflammatory capabilities by providing an antibacterial drug nanocarrier that responds to ROS. When used as an antibacterial drug carrier, it can cooperate with each other in antibacterial and anti-inflammatory effects and reduce the dosage of the antibacterial drug.

[0024] The ROS-responsive antibacterial drug nanocarrier provided by the present invention also has good adhesion to bacteria, thereby improving the bioavailability of the drug and achieving better antibacterial treatment effects on the basis of reducing the number of drug administrations.

[0025] When the ROS-responsive antibacterial drug nanocarrier provided by the present invention is used as a carrier of ocular anti-inflammatory drugs, it increases the adhesion of ocular surface drugs and increases the retention time of antibacterial drugs on the ocular surface. At the same time, by improving the solubility of antibacterial drugs, it solves the problem that ocular anti-inflammatory drugs are prone to precipitation and irritation of the eyes in the ocular environment, and reduces the dosage of antibacterial drugs and the effective antibacterial concentration. Bacterial keratitis is treated by coating antibiotics, and the excess active oxygen in the local area is eliminated, promoting the healing process of bacterial keratitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 Figure A shows P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 The synthesis process model diagram, namely PPM;

[0027] Figure 1 B is P(PEGMA 10 -co-BAA 2 )-b-PMTEMA 25 The synthesis process model diagram, namely PAM;

[0028] Figure 2 A is P(PEGMA 10 -co-PBA2 )-b-PMTEMA 25 Synthetic 1 H NMR spectrum;

[0029] Figure 2 B is P(PEGMA 10 -co-BAA 2 )-b-PMTEMA 25 Synthetic 1 H NMR spectrum;

[0030] Figure 3 A is the particle size diagram of polymer vesicles PPM and drug-loaded vesicles CIP@PPM;

[0031] Figure 3 B is the TEM and SEM images of PPM and CIP@PPM;

[0032] Figure 3 C is the UV spectrum of CIP@PPM;

[0033] Figure 3 D is the particle size diagram of the control group polymer vesicles PAM and drug-loaded vesicles CIP@PAM;

[0034] Figure 3 E is the TEM images of PAM and CIP@PAM;

[0035] Figure 3 F is the UV spectrum of CIP@PAM;

[0036] Figure 4 A is the CCK8 experimental detection diagram of cytotoxicity of PPM and CIP@PPM;

[0037] Figure 4 B is the cytotoxic live-dead staining of PPM and CIP@PPM;

[0038] Figure 4 C is the CCK8 experimental detection diagram of the cytotoxicity of PAM and CIP@PAM;

[0039] Figure 5 A is the UV spectrum of PPM removing ·OH evaluated by ABTS method;

[0040] Figure 5 B is a representative fluorescence image of PPM scavenging cellular reactive oxygen species evaluated by ROS response probe;

[0041] Figure 6 A is H 2 O 2 Representative images of stimulated release CIP inhibition zone experiments;

[0042] Figure 6 B is H 2 O 2 Quantitative analysis of the stimulated release CIP inhibition zone experiment;

[0043] Figure 7 Confocal 3D images comparing the bacterial adhesion abilities of PAM and PPM loaded with FITC green fluorescence;

[0044] Figure 8 A is a slit lamp comparison image before and 7 days after topical administration;

[0045] Figure 8 B is a representative picture of TUNEL staining of corneal tissue 7 days after administration;

[0046] Fig. 9 Representative confocal images of the comparison of the corneal penetration ability of PAM and PPM loaded with FITC green fluorescence (green) and the validation of anti-Staphylococcus aureus antibody on the infected cornea model (red);

[0047] Fig.10 A is a representative image of the slit lamp during treatment;

[0048] Fig.10 B is the corneal scoring quantification diagram;

[0049] Fig.10 C is the structural morphology of the cornea evaluated by H&E staining seven days after treatment;

[0050] Fig.10 D is the result of homogenate smear of cornea after treatment;

[0051] Fig.11 Representative images of IL-1β and TNF-α immunofluorescence. DETAILED DESCRIPTION

[0052] The present invention will be further described in detail below with reference to embodiments and effect examples, but the scope of the present invention is not limited thereto.

[0053] Example 1 P (PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 Synthesis

[0054] 4-Cyano-4-(phenylthioformylthio) valeric acid, polyethylene glycol methacrylate, 3-acrylamidophenylboronic acid and azobisisobutyronitrile were added to a glass bottle at a molar ratio of 1:10:2:0.5, and then dissolved in N,N-dimethylformamide. The solution was then bubbled with nitrogen in an ice bath for 30 minutes, and the glass bottle was placed in an oil bath at 70°C and stirred at 200 rpm. After polymerization under nitrogen for 6.5 hours, the glass bottle was taken out of the oil bath, and the resulting solution was exposed to air to terminate the polymerization. After dialyzing in water for 48 hours using a 2000Da dialysis bag, it was vacuum freeze-dried for 38 hours to obtain the product macromolecular chain transfer agent P(PEGMA 10 -co-PBA 2 )-CTA.

[0055] Then, P(PEGMA 10 -co-PBA 2 )-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile were added to a glass bottle at a molar ratio of 1:25:0.5, and then dissolved in 1.85 mL of methanol. The solution was then bubbled with nitrogen in an ice bath for 30 minutes, and the glass bottle was placed in an oil bath at 60°C and stirred at 200 rpm. After polymerization under nitrogen for 12 hours, the glass bottle was taken out of the oil bath and the resulting solution was exposed to air to terminate the polymerization. The product was centrifuged and washed with methanol, and the obtained product was vacuum concentrated and dried for 9 hours to obtain a diblock polymer P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 Its synthesis method is as follows Figure 1 As shown in A, the product 1 H NMR spectroscopy Figure 2 As shown in A, it means that the final product is indeed P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 .

[0056] Comparative Example 1P(PEGMA 10 -co-BAA 2 )-b-PMTEMA 25 Synthesis

[0057] 4-Cyano-4-(phenylthioformylthio) pentanoic acid, polyethylene glycol methacrylate, n-butyraldehyde aniline condensate and azobisisobutyronitrile were added to a glass bottle at a molar ratio of 1:10:2:0.5, and then dissolved in N,N-dimethylformamide. The solution was then bubbled with nitrogen in an ice bath for 30 minutes, and the glass bottle was placed in an oil bath at 70°C and stirred at 200 rpm. After polymerization under nitrogen for 6.5 hours, the glass bottle was taken out of the oil bath, and the resulting solution was exposed to air to terminate the polymerization. After dialyzing in water for 48 hours using a 2000Da dialysis bag, it was vacuum freeze-dried for 38 hours to obtain the product macromolecular chain transfer agent P(PEGMA 10 -co-PBA 2 )-CTA.

[0058] Then, P(PEGMA 10 -co-PBA 2 )-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile were added to a glass bottle at a molar ratio of 1:25:0.5, and then dissolved in 1.85 mL of methanol. The solution was then bubbled with nitrogen in an ice bath for 30 minutes, and the glass bottle was placed in an oil bath at 60°C and stirred at 200 rpm. After polymerization under nitrogen for 12 hours, the glass bottle was taken out of the oil bath and the resulting solution was exposed to air to terminate the polymerization. The product was centrifuged and washed with methanol, and the obtained product was vacuum concentrated and dried for 9 hours to obtain a diblock polymer P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 Its synthesis method is as follows Figure 1 As shown in B, the product 1 H NMR spectroscopy Figure 2 As shown in B, it means that the final product is indeed P(PEGMA 10 -co-BAA 2 )-b-PMTEMA 25 .

[0059] Example 2 Preparation of drug-loaded vesicles CIP@PPM

[0060] P(PEGMA 10 -co-PBA 2 )-b-PMTEMA 25 The diblock copolymer was dissolved in azobisisobutyronitrile, and then an aqueous solution of ciprofloxacin (CIP) was slowly added dropwise under continuous stirring to obtain CIP vesicles. The CIP vesicle dispersion was then transferred to a 7000Da dialysis bag and dialyzed in deionized water for 3 h. The dialysate was replaced every half an hour to remove residual azobisisobutyronitrile and free ciprofloxacin (CIP) to obtain drug-loaded vesicles CIP@PPM.

[0061] Comparative Example 2 Preparation of drug-loaded vesicles CIP@PAM

[0062] P(PEGMA 10 -co-BAA 2 )-b-PMTEMA 25 The diblock copolymer was dissolved in azobisisobutyronitrile, and then an aqueous solution of ciprofloxacin (CIP) was slowly added dropwise under continuous stirring to obtain CIP vesicles. The CIP vesicle dispersion was then transferred to a 7000Da dialysis bag and dialyzed in deionized water for 3 h. The dialysate was replaced every half an hour to remove residual azobisisobutyronitrile and free ciprofloxacin (CIP) to obtain drug-loaded vesicles CIP@PAM.

[0063] Example 3 Physicochemical properties of PAM, CIP@PPM prepared in Example 1-2 and Comparative Example 1-2

[0064] The hydrodynamic diameter (Dh) and dispersion index (PDI) of PPM and PAM measured by dynamic light scattering instrument, such as Figure 3 As shown, the dynamic light scattering measurement (DLS) results showed that the hydrodynamic diameter (Dh) of PPM and PAM was 203.6nm ( Figure 3 A) and 210.2nm( Figure 3 C), the morphology of PPM and PAM was confirmed by transmission electron microscopy (TEM) ( Figure 3 B, Figure 3 D). The size of PPM and PAM observed by transmission electron microscopy is consistent with the DLS study. The dispersion index (PDI) of PPM and CIP@PPM is 0.042 ( Figure 3 A) and 0.033nm( Figure 3 C), indicating that the drug-loaded particles have good uniformity. Figure 3 As shown in A, the size (size distribution) of CIP@PPM is 247.1 (0.002). The larger size of the CIP-loaded vesicles compared to the corresponding blank vesicles (PPM) is due to the encapsulation of the drug. TEM results show that CIP-PPM is still a vesicle, but compared to PPM, there is drug loading in the middle. SEM results also show that CIP@PPM shrinks due to the vesicular morphology of the nanoparticles in the dry state. The experiment also proved that the nanoparticles are vesicular in shape, and their particle size is consistent with the DLS results. The successful encapsulation of the drug was demonstrated by UV spectroscopy, and mapping also observed the F element signal contained in CIP inside the vesicles, Figure 3 As shown in E and F.

[0065] Example 4 Cytotoxicity of PPM and CIP@PPM prepared in Example 1 and Example 2

[0066] HCECs in the logarithmic growth phase were used as target cells (T); they were inoculated into 96-cell plates at an E:T ratio of 10:1, and gradient dilutions of PPM or CIP@PPM were added. The cells were incubated at 37°C for 48 h, and the cytotoxicity of PPM and CIP@PPM was analyzed using the Enhanced Cell Counting Kit-8 (CCK-8, Beyotime) and Calcein / PI cell activity and cytotoxicity detection kit (Beyotime). Figure 4 As shown in A and C, the cell viability in Figure 4A is above 85%. Figure 4 More than 95% of cells in B are living cells (green), indicating that PPM or CIP@PPM is not toxic to cells.

[0067] The same method was used to evaluate the biocompatibility of PAM and CIP@PAM of Comparative Example 1 and Comparative Example 2. The results are as follows: Figure 4 As shown in C, the cell viability was above 85%, indicating that it had no toxicity to the cells.

[0068] Example 5 ROS scavenging effect of PPM

[0069] The antioxidant capacity of PPM was measured by measuring the scavenging effect of PPM on OH· using ABTS. The absorbance was measured at 730nm using a UV-visible spectrophotometer. Figure 5 As shown in A, PPM has antioxidant capacity.

[0070] HCECs were seeded in 96-well plates at a cell density of 5 × 10 3 After 24 hours of cell incubation, the medium was replaced with DMEM-F12 medium without FBS containing 300 μM hydrogen peroxide to simulate a high reactive oxygen environment. HCECs cultured under normal conditions served as the control group. Then, 30 μg / mL PPM and CIP@PPM were added to the wells and incubated for 24 hours. The intracellular ROS level was measured using CM-H2DCFDA (Invitrogen) according to the manufacturer's instructions. Figure 5 As can be seen in B, the fluorescence intensity of reactive oxygen species in the PPM group decreased, indicating that PPM has the effect of scavenging ROS.

[0071] Example 6 ROS targeting of CIP@PPM

[0072] 5 mm sterile filter paper was soaked in solutions containing different materials for 4 hours, namely PBS, H 2 O 2 , CIP, PAM, PPM, CIP@PPM, CIP@PAM, CI P@PPM+H 2 O2 、CIP@PAM+H 2 O 2 Treatment, in which the CIP content is almost the same. A single colony of Staphylococcus aureus was cultured in TSB medium for 7 hours, the bacterial culture solution was added to the TSA medium that was sterilized and cooled to a suitable temperature, and then 20mL of the bacteria-containing TSA medium was poured into the bacterial culture dish. After the bacteria-containing TSA medium was completely cooled and solidified, it was divided into four parts, and then the drug-loaded filter paper of each group was placed on the bacteria-containing medium. After constant temperature culture at 37°C for 24 hours, photos were taken to observe the size of the inhibition zone.

[0073] The results are as follows Figure 6 As shown, high H 2 O 2 The concentration can promote the acceleration of CIP release from CIP@PPM and CIP@PAM particles, indicating that CIP@PPM has ROS targeting.

[0074] Example 7 Bacterial Adhesion of PPM

[0075] 500 μL of Staphylococcus aureus suspension (about 10 8 CFU / mL) was mixed with 500 μL FITC@PPM or FITC@PAM solution in a 24-well plate and incubated overnight in a 37°C shaker. Centrifuge at 9000 g for 10 min, suspend the cells with 1 mL PBS, and then stain the bacteria with 4',6-diamidino-2-phenylindole (DAPI) solution. After standing in the dark for 15 minutes, the stained bacterial solution was cured on a slide and sealed. Laser confocal microscopy was used for further observation. The results are shown in Figure 2. Figure 7 As shown in the confocal 3D image, the overlap ratio of PPM (green) and bacteria (blue) in the PPM group was significantly higher than that in the PBM group, indicating that PPM has good adhesion to bacteria.

[0076] Example 8 Construction of bacterial keratitis animal model

[0077] The experimental animals used in this study were 30 female C57BL / 6j mice aged 6-8 weeks. The experimental animals were provided by the Experimental Animal Center of Wenzhou Medical University and approved by the Experimental Animal Ethics Committee of Wenzhou Medical University. The mice were housed under an intelligent environmental control system (relative humidity 30±5%, wind speed 2.1±0.2m / s, temperature 21-23℃), and there were 5 experimental groups, with 6 mice in each group.

[0078] Model construction: After anesthetizing mice, the cornea was scraped to the superficial stroma layer with a sterile scalpel, and the cornea was damaged by about 1 mm. The concentration used was 3-5×10 8CFU / mL of Staphylococcus aureus was used for infection. Within 24 hours after the addition of the bacterial suspension, the mice were not disturbed to promote the development of bacterial keratitis.

[0079] The experiment was randomly divided into six groups: negative control group (PBS group), positive control group (CIP group), control experimental group (PPM, PAM, CIP@PAM), and experimental group (CIP@PPM group). Each mouse was instilled with 10 μL of the treatment drug into the eye every day, 5 μL / eye (twice a day), for one week. By measuring the CIP content in the CIP@PAM and CIP@PPM groups, the CIP@PAM, CIP@PPM and CIP groups were given almost the same dose of CIP.

[0080] Example 9 Biocompatibility of PPM, PAM, CIP@PAM, and CIP@PPM in Animal Experiments

[0081] To verify the effect of nano-drug-loaded particles on the cornea, PPM, PAM, CIP@PAM, and CIP@PPM were administered topically to the eye three times a day (5 μL / eye) for one week. Corneal health was examined using a slit lamp microscope under natural light. Subsequently, the cornea was stained with sodium fluorescein, and corneal epithelial defects were examined under cobalt blue light using a slit lamp microscope to assess the extent of epithelial defects. Hematoxylin-eosin (H&E) staining was used to observe pathological changes in the staining of tissue sections of the cornea, iris, and sclera of mice in each group. Apoptosis in the cornea was detected according to the instructions of the one-step TUNEL apoptosis detection kit (Biyuntian). Slit lamp examination indicated that the cornea was smooth and transparent, without congestion or corneal opacity. After fluorescent staining, the corneal epithelium was intact and unstained ( Figure 8 A). Almost no apoptotic cells were observed in the cornea ( Figure 8 B), indicating that PPM, PAM, CIP@PAM, and CIP@PPM have good biocompatibility.

[0082] Example 10 Adhesion performance of PPM and PAM to bacteria in bacterial keratitis model

[0083] To evaluate the penetration and persistence of FITC-loaded drug carriers in the cornea after topical administration, 10 μL of the reagent was dropped into the eyes of the animals every 10 minutes, 5 μL / eye. Four hours after topical administration, corneal tissues were incubated with anti-S. aureus specific antibodies (Abcam) and Cy3-conjugated goat anti-rabbit secondary antibodies (proteintech) at 37°C for 1 hour. The distribution of FITC@PAM or FITC@PPM in S. aureus-infected corneas 4 hours after administration was observed using confocal laser scanning microscopy. Fig. 9It can be seen that the red fluorescence signal is clearly distributed in the cornea, reflecting the presence of Staphylococcus aureus cells, proving the success of the bacterial keratitis model. In addition, 4 hours after topical administration, the adhesion function of PBA-based FITC@PPM is better than that of CIP@PAM, and even some nanoparticles have penetrated the epithelium and entered the stroma, showing good corneal penetration ability in vivo.

[0084] Example 11 Therapeutic effect of drug-loaded vesicles on bacterial keratitis

[0085] CIP, PAM, PPM, CIP@PPM, and CIP@PAM were used to treat bacterial keratitis models. Each mouse was instilled with 10 μL of the drug into the eye every day, 5 μL / eye (twice a day) for one week. The corneal tissue was extracted and homogenized, and the number of residual bacteria was determined by coating on TSB plates. Fig.10 As shown in Figure C, the CFU counts in the CIP@PPM group were much lower than those in the PBS and PAM groups (p<0.01), indicating that topical application of CIP@PPM has a significant antibacterial effect, which is more significant than using CIP alone. In order to observe the healing effect of CIP@PPM on bacterially infected corneas, representative images of corneal opacity were taken 7 days after treatment. At the same time, the corneal opacity score was recorded to further determine the healing effect from a quantitative perspective. Fig.10 As shown in A and B, the corneal opacity score of the CIP@PPM group was significantly lower than that of the PBS group and the PAM group (P<0.05), and slightly lower than that of the CIP, PPM, and CIP@PAM groups, indicating that CIP@PPM can significantly reduce corneal opacity and has the best anti-infection therapeutic effect. The results of H&E staining are shown in Fig.10 C. In the PBS and PAM groups, abnormal corneal structures such as corneal edema and thickening, as well as a large number of infiltrating inflammatory cells were observed. Secondly, there were also edematous abnormal structures and a small amount of inflammatory cell infiltration in the central cornea of ​​the PPM group. However, in CIP, CIP@PPM and CIP@PAM, corneal edema subsided, the corneal structure basically returned to normal, and the fibrous matrix layer was neatly arranged. In CIP@PPM, the fibrous matrix layer was more neat and the corneal edema abnormal structure was less.

[0086] Example 12 Effect of drug-loaded vesicles on inflammatory factors in bacterial keratitis

[0087] The expression and localization of inflammatory factors (TNF-α and IL-1β) in the cornea were evaluated by immunofluorescence staining experiments. The dewaxed sections were first repaired with antigen repair solution, and then treated with PBS solution containing 3% bovine serum albumin to reduce nonspecific reactions. Then, the samples were treated with a solution containing anti-IL-6 monoclonal antibody and anti-TNF-α polyclonal antibody. The samples were incubated with FITC-conjugated TNF-α goat anti-rabbit IgGpAbs (green) and Cy3-conjugated IL-1β goat anti-mouse IgGpAbs (red) at 37°C for 1 hour. Finally, the tissue was incubated with diluted DAPI at room temperature and observed by fluorescence microscopy (LSM880NLOwithAiryScan). The results are shown in Figure 2. Fig.11 As shown, in the PBS and PAM groups, TNF-α levels (green fluorescence) were evenly distributed in the corneal epithelium and stroma, while almost no expression was found in the corneal stroma treated with PPM, CIP@PAM, and CIP. In the PBS, PAM, PPM, and CIP groups, IL-1β (red fluorescence) was expressed in the cornea. The fluorescence intensity of these two inflammatory factors was significantly reduced after treatment with PPM, CIP@PAM, and CIP@PPM. The lowest fluorescence intensity was observed in CIP@PPM, with only a little red and green. Therefore, CIP@PPM can further reduce the intensity of inflammatory factors and inhibit the secretion of inflammatory factors.

[0088] Finally, it is necessary to explain here that the above embodiments are only used to further illustrate the technical solution of the present invention in detail and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above content of the present invention all fall within the scope of protection of the present invention.

Claims

1. A ROS-responsive antimicrobial drug nanocarrier, characterized in that: Including two-block polymer P(PEGMA 10 -co-PBA2)-b-PMTEMA 25 , the P(PEGMA 10 -co-PBA2)-b-PMTEMA 25 It has the structure shown below:

2. An antibacterial drug-loaded vesicle, characterized in that: The invention comprises the ROS-responsive antibacterial drug nanocarrier and the antibacterial agent as described in claim 1.

3. The antibacterial drug-loaded vesicle according to claim 2, characterized in that: The antibacterial agent is a fluoroquinolone drug.

4. The antibacterial drug-loaded vesicle according to claim 3, characterized in that: The antibacterial agent is ciprofloxacin.

5. Use of the antibacterial drug-loaded vesicle according to any one of claims 2 to 4, characterized in that: The use is the use of antibacterial drug-loaded vesicles in the preparation of drugs for treating bacterial eye inflammation.

6. The use according to claim 5, characterized in that: The use is the use of antibacterial drug-loaded vesicles in the preparation of drugs for treating bacterial keratitis.

7. The method for preparing the ROS-responsive antibacterial drug nanocarrier according to claim 1, characterized in that: Step 1: Preparation of macromolecular chain transfer agent P(PEGMA 10 -co-PBA2)-CTA 4-cyano-4-(phenylthioformylthio) valeric acid, polyethylene glycol methacrylate, 3-acrylamidophenylboronic acid and azobisisobutyronitrile were mixed and dissolved in N,N-dimethylformamide, and then the solution was bubbled with nitrogen for 20-60 minutes in an ice bath, and polymerized under nitrogen for 5-10 hours at a low speed under a hot bath condition of 70°C. The resulting solution was exposed to air to terminate the polymerization, and dialyzed in water using a 2000Da dialysis bag, and vacuum freeze-dried to obtain the product macromolecular chain transfer agent P(PEGMA 10 -co-PBA2)-CTA; Step 2: Preparation of block polymer P(PEGMA 10 -co-PBA2)-b-PMTEMA 25 P(PEGMA) prepared in step 1 10 -co-PBA2)-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile were mixed and dissolved in methanol, and then the solution was bubbled with nitrogen in an ice bath for 20-60 minutes, and then stirred at a low speed in a hot bath at 60°C. After polymerization for 10-15 hours under nitrogen, the resulting solution was exposed to air to terminate the polymerization, and the product was centrifuged and washed with methanol. The obtained product was vacuum concentrated and dried to obtain a diblock polymer P(PEGMA 10 -co-PBA2)-b-PMTEMA 25 .

8. A method for preparing a ROS-responsive antibacterial drug nanocarrier according to claim 7, characterized in that: The molar ratio of 4-cyano-4-(phenylthioformylthio)pentanoic acid, polyethylene glycol methacrylate, 3-acrylamidophenylboronic acid and azobisisobutyronitrile in step 1 is 1:10:2:0.

5.

9. A method for preparing a ROS-responsive antimicrobial drug nanocarrier according to claim 7, characterized in that: P(PEGMA) in step 2 10 The molar ratio of -co-PBA2)-CTA, ethyl 2-(methylthio)methacrylate and azobisisobutyronitrile is 1:25:0.

5.

10. The method for preparing the antibacterial drug-loaded vesicles according to any one of claims 2 to 4, characterized in that: P(PEGMA 10 -co-PBA2)-b-PMTEMA 25 The diblock copolymer was dissolved in N,N-dimethylformamide, and then the CIP aqueous solution was slowly added dropwise under continuous stirring to prepare CIP vesicles. The CIP vesicle dispersion was then transferred to a 7000Da dialysis bag and dialyzed in deionized water for 3 h to remove residual N,N-dimethylformamide and free CIP to obtain drug-loaded vesicles CIP@PPM.

Citation Information

Cited By

  • Cell membrane modified inflammation responsive release nanoparticles as well as preparation method and application thereof

    CN122124281A